These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17481739)

  • 1. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
    De Clercq E; Neyts J
    Trends Pharmacol Sci; 2007 Jun; 28(6):280-5. PubMed ID: 17481739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future antiviral therapy of severe seasonal and avian influenza.
    Beigel J; Bray M
    Antiviral Res; 2008 Apr; 78(1):91-102. PubMed ID: 18328578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
    Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
    Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivirals for influenza: historical perspectives and lessons learned.
    Hayden FG
    Antiviral Res; 2006 Sep; 71(2-3):372-8. PubMed ID: 16815563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral management of seasonal and pandemic influenza.
    Hayden FG; Pavia AT
    J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
    Jacob A; Sood R; Chanu KhV; Bhatia S; Khandia R; Pateriya AK; Nagarajan S; Dimri U; Kulkarni DD
    Microb Pathog; 2016 Feb; 91():35-40. PubMed ID: 26639679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
    Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
    Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivirals and influenza: frequency of resistance.
    Monto AS
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.
    Moorthy NS; Poongavanam V; Pratheepa V
    Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
    Sood R; Kumar N; Bhatia S; Chanu KV; Gupta CL; Pateriya AK; Mishra A; Khandia R; Mawale N; Singh VP
    Antiviral Res; 2018 Oct; 158():143-146. PubMed ID: 30125616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
    Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
    Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the structure-based design of the influenza A neuraminidase inhibitors.
    Mitrasinovic PM
    Curr Drug Targets; 2010 Mar; 11(3):315-26. PubMed ID: 20210756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuraminidase inhibitors and risk of H5N1 influenza].
    Gras-Masse H; Willand N
    Ann Pharm Fr; 2007 Jan; 65(1):50-7. PubMed ID: 17299351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivirals--current trends in fighting influenza.
    Król E; Rychłowska M; Szewczyk B
    Acta Biochim Pol; 2014; 61(3):495-504. PubMed ID: 25180220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The threat of avian influenza A (H5N1). Part III: Antiviral therapy.
    Cinatl J; Michaelis M; Doerr HW
    Med Microbiol Immunol; 2007 Dec; 196(4):203-12. PubMed ID: 17431677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Present and future in development of new anti-influenza drugs].
    Watanabe A
    Nihon Rinsho; 2010 Sep; 68(9):1685-9. PubMed ID: 20845748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.